Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hexavalent recombinant norovirus vaccine
- Development stage
- Phase 2
- Lead developer
- Grand Theravac Life Science Nanjing
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The hexavalent recombinant norovirus vaccine is a virus-like particle (VLP) vaccine candidate developed by Grand-Sevax Life Sciences for the prevention of norovirus-induced acute gastroenteritis. Noroviruses are highly contagious and genetically diverse, categorized into multiple genogroups and genotypes. This vaccine is engineered to express the major capsid protein (VP1) of six distinct norovirus genotypes, typically covering both Genogroup I (GI) and Genogroup II (GII) strains, which are responsible for the majority of human infections. By mimicking the structure of the native virus without containing infectious genetic material, the VLPs induce a robust neutralizing antibody response against the targeted strains. The vaccine aims to provide broad-spectrum protection against the most prevalent circulating strains of norovirus, addressing a significant unmet need in global public health.
- Other names
- hexavalent norovirus VLP vaccine6-valent recombinant norovirus vaccinerecombinant hexavalent norovirus virus-like particle vaccine
02
Targets
Norovirus VP1
Beyond the preview
Go deeper on hexavalent recombinant norovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hexavalent recombinant norovirus vaccine.